On February 28, 2019, a series of requirements will go into effect as a result of FDA’s modification to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program. Of note, is a requirement for health care professionals prescribing clozapine, as well as pharmacies dispensing clozapine, to be certified in the clozapine REMS program. This session will discuss these new requirements and address participant questions.
This event is not designated for AMA PRA Category 1 CreditTM.
Register at SMIadviser.org/REMS